Alembic Pharmaceuticals Limited

NSE APLLTD.NS

Alembic Pharmaceuticals Limited Revenue Per Share for the year ending March 31, 2024: USD 3.80

Alembic Pharmaceuticals Limited Revenue Per Share is USD 3.80 for the year ending March 31, 2024, a 8.58% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.

Alembic Pharmaceuticals Limited Revenue Per Share for the year ending March 31, 2023 was USD 3.50, a -0.18% change year over year.
Alembic Pharmaceuticals Limited Revenue Per Share for the year ending March 31, 2022 was USD 3.51, a -5.75% change year over year.
Alembic Pharmaceuticals Limited Revenue Per Share for the year ending March 31, 2021 was USD 3.72, a 17.62% change year over year.
Alembic Pharmaceuticals Limited Revenue Per Share for the year ending March 31, 2020 was USD 3.16, a 8.82% change year over year.

Key data

Date	Revenue Per Share	Dividend Per Share	Free Cash Flow Per Share	Return on Assets (ROA)

NSE: APLLTD.NS

Alembic Pharmaceuticals Limited

CEO	Mr. Chirayu Ramanbhai Amin
IPO Date	Sept. 20, 2011
Location	India
Headquarters	Alembic Road
Employees	14,858
Sector	Health Care
Industries Pharmaceuticals

Description

Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients and formulations. The company also provides branded and generic formulations in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, and anti-diabetic. In addition, it exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.

Key trends

Past 5 years